Lunai Bioworks Inc. LNAI
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-379.62
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$178.0M | — | — | -$21.3M |
| 2024 | — | -$88.4M | — | -$11.0M | $132.0M |
| 2023 | — | -$39.7M | — | -$11.8M | $46.5M |
| 2022 | — | -$113.4M | — | -$15.7M | $72.6M |
| 2021 | — | -$26.7M | — | -$20.7M | $174.7M |
| 2020 | — | -$11.4M | — | -$10.6M | $166.3M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -379.62 (distress)
- Working capital / assets -3.415
- Retained earnings / assets -62.018
- EBIT / assets -22.958
- Equity / liabilities -0.722
Source: SEC EDGAR filings · CIK 0001527728 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.